AbbVie entered 2025 with very strong momentum, as confirmed by its newly released first quarter financial results. After years of structural changes as the company dealt with the impact of patent expirations on its key drug Humira, the new strategy appears to be bearing fruit. Robust revenue growth in key therapeutic areas such as immunology and neuroscience points to successful portfolio diversification and a successful focus on innovative products, notably Skyrizi and Rinvoq.

The results of $ABBV indicate not only a stabilization of revenues but also a gradual recovery in operating performance. Nevertheless, it cannot be overlooked that the company is still facing pressure on profitability - mainly due to a sharp increase in expenses and a gradual transformation of the product portfolio.

How was the last quarter?

AbbVie reported financial results for the first quarter of 2025 that beat expectations and point to a strong start to the year. Worldwide net sales were $13.343 billion, up 8.4…